Summit Therapeutics Quarterly Income Statements Chart
Quarterly
|
Annual
Summit Therapeutics Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| operating expenses: | ||||||||||||||||||||
| research and development | 208,021,000 | 51,265,000 | 51,382,000 | 37,724,000 | 30,798,000 | 30,873,000 | 24,814,000 | 15,323,000 | 9,451,000 | 9,883,000 | 5,386,000 | 17,049,000 | 9,008,000 | 20,556,000 | 23,107,000 | 19,943,000 | 23,923,000 | 18,379,000 | 94,253,000 | -14,387,000 |
| acquired in-process research and development | ||||||||||||||||||||
| general and administrative | 360,416,000 | 15,586,000 | 14,437,000 | 20,390,000 | 13,971,000 | 11,729,000 | 11,575,000 | 5,434,000 | 6,316,000 | 6,940,000 | 7,578,000 | 5,573,000 | 6,933,000 | 6,659,000 | 7,780,000 | 5,662,000 | 5,984,000 | 4,185,000 | 32,662,000 | -7,460,000 |
| total operating expenses | 568,437,000 | 66,851,000 | 65,819,000 | 58,114,000 | 59,776,000 | 42,602,000 | 36,389,000 | 20,757,000 | 15,767,000 | 537,738,000 | 21,432,000 | 22,622,000 | 15,941,000 | 27,215,000 | 30,887,000 | 25,605,000 | 29,907,000 | 22,564,000 | 128,633,000 | -22,706,000 |
| other income | 2,729,000 | 3,938,000 | 13,097,000 | 2,124,000 | -768,000 | -1,084,000 | -357,000 | -776,000 | 1,077,000 | -5,222,000 | 1,070,000 | -4,445,000 | -4,079,000 | 761,000 | -1,052,000 | -113,000 | -686,000 | -565,000 | -13,000 | 416,000 |
| interest expense | ||||||||||||||||||||
| net income | -565,708,000 | -62,913,000 | -61,203,000 | -56,254,000 | -60,385,000 | -43,473,000 | -36,567,000 | -21,268,000 | -14,717,000 | -542,376,000 | -19,229,000 | -21,385,000 | -16,771,000 | -21,397,000 | -27,099,000 | -19,599,000 | -24,416,000 | -17,488,000 | -13,442,000 | -17,701,000 |
| yoy | 836.84% | 44.72% | 67.37% | 164.50% | 310.31% | -91.98% | 90.17% | -0.55% | -12.25% | 2434.82% | -29.04% | 9.11% | -31.31% | 22.35% | 101.60% | 10.72% | ||||
| qoq | 799.19% | 2.79% | 8.80% | -6.84% | 38.90% | 18.89% | 71.93% | 44.51% | -97.29% | 2720.61% | -10.08% | 27.51% | -21.62% | -21.04% | 38.27% | -19.73% | 39.62% | 30.10% | -24.06% | |
| net income margin % | -9720.45% | -7136.60% | -8558.80% | -10796.41% | -1497.25% | -42835.09% | -9108.33% | -7265.95% | -9779.56% | |||||||||||
| net income per share | ||||||||||||||||||||
| basic and diluted | -0.76 | -0.09 | -0.09 | -0.08 | -0.09 | -0.06 | -0.01 | -0.03 | -0.02 | -1.43 | 0.11 | -0.14 | -0.17 | -0.22 | -0.28 | -0.2 | ||||
| weighted-average common shares outstanding: | ||||||||||||||||||||
| basic and diluted | 742,615,007 | 738,076,003 | 718,541,896 | 726,656,045 | 707,904,643 | 701,785,250 | 619,646,180 | 697,739,477 | 697,685,365 | 378,163,980 | 193,336,063 | 148,582,751 | 99,654,092 | 98,070,095 | 92,239,306 | 97,452,628 | 90,650,854 | 82,817,836 | ||
| other comprehensive loss: | ||||||||||||||||||||
| foreign currency translation adjustments | -189 | -145 | 235 | -155 | 92 | -12 | -152 | 108 | -76 | -51 | 1,324 | -49 | 789 | -1,760 | 1,245 | -863 | ||||
| reclassification of unrealized loss on short-term investments to other income | ||||||||||||||||||||
| unrealized loss on short-term investments | ||||||||||||||||||||
| comprehensive loss | -565,897 | -63,191 | -61,180 | -56,063 | -60,335 | -43,474 | -36,692 | -21,154 | -15,758 | -541,878 | -17,905 | -21,434 | -15,982 | -23,157 | -25,854 | -20,462 | -23,876 | -16,813 | ||
| unrealized (loss)/gains on short-term investments | -133 | |||||||||||||||||||
| revenue | 220,000 | 235,000 | 250,000 | 251,000 | 1,309,000 | 57,000 | 192,000 | 185,000 | 181,000 | |||||||||||
| yoy | -83.19% | 312.28% | 30.21% | 35.68% | 623.20% | |||||||||||||||
| qoq | -6.38% | -6.00% | -0.40% | -80.83% | 2196.49% | -70.31% | 3.78% | 2.21% | ||||||||||||
| other operating income | 205,000 | -264,000 | 159,000 | 213,000 | 179,000 | 265,000 | -27,000 | 584,000 | 1,133,000 | 5,462,000 | 3,014,000 | 4,807,000 | 4,589,000 | 4,810,000 | 6,120,000 | 5,449,000 | 4,363,000 | 4,309,000 | ||
| operating income | -65,614,000 | -58,378,000 | -59,617,000 | -42,389,000 | -36,210,000 | -20,492,000 | -15,794,000 | -537,154,000 | -20,299,000 | -16,940,000 | -12,692,000 | -22,158,000 | -26,047,000 | -19,486,000 | -23,730,000 | -16,923,000 | -9,911,000 | -18,216,000 | ||
| yoy | 81.20% | 184.88% | 277.47% | -92.11% | 78.38% | 20.97% | 24.44% | 2324.20% | -22.07% | -13.07% | -46.51% | 30.93% | 162.81% | 6.97% | ||||||
| qoq | 12.40% | -2.08% | 40.64% | 17.06% | 76.70% | 29.75% | -97.06% | 2546.21% | 19.83% | 33.47% | -42.72% | -14.93% | 33.67% | -17.88% | 40.22% | 70.75% | -45.59% | |||
| operating margin % | -7700.00% | -5400.85% | -8863.20% | -10377.29% | -1488.62% | -41631.58% | -8814.06% | -5357.30% | -10064.09% | |||||||||||
| weighted-average shares used for eps calculation | ||||||||||||||||||||
| basic and diluted | 742,615,007 | 738,076,003 | 718,541,896 | 726,656,045 | 707,904,643 | 701,785,250 | 619,646,180 | 697,739,477 | 697,685,365 | 378,163,980 | 193,336,063 | 148,582,751 | 99,654,092 | 98,070,095 | 92,239,306 | 97,452,628 | 90,650,854 | 82,817,836 | ||
| comprehensive loss: | ||||||||||||||||||||
| other comprehensive income: | ||||||||||||||||||||
| reclassification of cumulative currency translation gain to other income | -419 | |||||||||||||||||||
| net unrealized gains on short-term investments | 78 | 346 | ||||||||||||||||||
| acquired in process research and development | 15,007,000 | |||||||||||||||||||
| reclassification of unrealized loss on investments to other income | 3 | |||||||||||||||||||
| net changes related to short-term investments | -45 | 11 | 2.25 | 6 | -965 | |||||||||||||||
| in-process research and development | 520,915,000 | |||||||||||||||||||
| unrealized gain on investments | 968 | |||||||||||||||||||
| impairment of intangible assets | ||||||||||||||||||||
| income before income tax | -27,099,000 | -19,599,000 | -24,416,000 | -9,837,000 | -17,800,000 | |||||||||||||||
| income tax benefit | 23,250 | 99,000 | ||||||||||||||||||
| loss per share: | ||||||||||||||||||||
| basic and diluted | -0.27 | -0.21 | ||||||||||||||||||
| change in foreign currency translation adjustment | 540 | 675 | ||||||||||||||||||
| income before income tax expense | -17,488,000 | |||||||||||||||||||
| income tax expense | ||||||||||||||||||||
| other comprehensive income / | ||||||||||||||||||||
| operating expenses | ||||||||||||||||||||
| impairment | -214,750 | -859,000 | ||||||||||||||||||
| basic loss per share | -0.145 | -0.26 | ||||||||||||||||||
| diluted loss per share | -0.145 | -0.26 | ||||||||||||||||||
| foreign currency translation adjustment | -578 | 2,255 | ||||||||||||||||||
| total comprehensive loss | -10,391.75 | -15,446 |
We provide you with 20 years income statements for Summit Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Summit Therapeutics stock. Explore the full financial landscape of Summit Therapeutics stock with our expertly curated income statements.
The information provided in this report about Summit Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.